2019 TAG Update
TAGline November 2019
About the HCV Project
Globally, over 58 million people are estimated to have hepatitis C virus (HCV). Despite the availability of all-oral, short-course direct-acting antivirals (DAAs) that treat all HCV genotypes, nearly half a million people die from this preventable, curable infection each year.…
Activist Guide to Hepatitis C Virus Diagnostics
Statement: Truly Corrective Actions on Drug Pricing Will Bring Life-Saving Benefit to Consumers in the U.S. and Globally
This is a joint statement from TAG and Health GAP October 16, 2019 – Although Speaker Nancy Pelosi’s bill to increase affordable access to medicines in the U.S., H.R. 3, offers halting, partial steps to reduce drug prices for some…
2019 Pipeline Report
Treatment Action Group Joins Collective Call Denouncing the Trump Administration’s Dangerous Finalized Anti-Immigrant Rule
Low- and Middle-Income Countries Defuse Hepatitis C, the “Viral Time Bomb”
June 2013 By Karyn Kaplan As rich countries prepare for a hepatitis C virus (HCV) treatment revolution, people in low- and middle-income countries (LMICs) remain without access to information, prevention tools, diagnostics, care, and treatment. A growing movement of global…
2013 EASL Update
Streamlining HCV Treatment By Tracy Swan Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations of direct-acting antivirals (DAAs) have pushed cure rates in HCV genotype 1 to over 90 percent. Still, we are…